Andrew Hack, a director at Nuvalent, Inc. (NASDAQ:NUVL), has recently sold a significant portion of the company's Class A Common Stock. According to a recent SEC filing, Hack disposed of 1.25 million shares at a price of $88 per share, totaling approximately $110 million. The transaction comes as the stock has experienced a 7.94% decline over the past week, though it maintains a market capitalization of $6.16 billion. According to InvestingPro, analysts maintain a bullish outlook with price targets ranging from $100 to $137. Following this transaction, Hack retains ownership of 1,447,267 shares indirectly and 2,499 shares directly.
The shares sold were held by Bain Capital Life Sciences Entities, where Hack is a partner. The filing notes that Hack shares voting and dispositive power over these securities but disclaims beneficial ownership, except for his pecuniary interest. This transaction marks a notable movement in Nuvalent's stock by one of its directors.
In other recent news, Nuvalent has made significant strides in its ongoing clinical trials. The pharmaceutical company has appointed Grant Bogle as an independent director to its board, a decision that aligns with the company's policies for board membership. According to BMO (TSX:BMO) Capital Markets, Nuvalent's recent business update, which included the announcement of reaching all its anticipated milestones for 2024, led to an increase in its price target to $134 from $132.
On the other hand, UBS initiated coverage on Nuvalent with a Neutral rating, indicating that the current stock price already reflects the near-term opportunity in non-small cell lung cancer (NSCLC) treatments. TD (TSX:TD) Cowen maintained a Buy rating on Nuvalent's shares, emphasizing the enrollment of over 200 patients in the Phase II programs.
Stifel financial firm also updated its outlook on Nuvalent, increasing the price target to $135 while maintaining a Buy rating. These recent developments reflect the ongoing efforts of Nuvalent to advance its clinical trials and deliver innovative treatments to patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.